PfizerPFE

01The operational increase was driven by an increase in revenues for Eliquis, Padcev, the Vyndaqel family, Lorbrena, Nurtec ODT/Vydura, Oncology biosimilars and several other products across categories Padcev is being jointly developed and commercialized with Astellas in the U.S., with Pfizer having commercialization rights in all countries in North and South America

02Pfizer is deploying a cumulative ~$10 billion savings program across SG&A and manufacturing to compress its cost base before peak LOE pressure in 2027-2030. Success would stabilize adjusted margins even as legacy products face generic erosion, converting a patent-cliff story into an efficiency story.

03We have reached final binding agreements with the U.S. Government; pursuant to the agreements, the applicable tariff rate under the April 2, 2026 Section 232 Executive Order for Pfizer products will be zero until January 20, 2029 We have not seen a significant disruption of our supply chain in the first six months of 2026 and all of our manufacturing sites globally have continued to operate at or near normal levels We do not anticipate the availability of raw materials to have a significant impact on our operations in 2026

04The Innovent deal adds 12 early-stage oncology assets—ADCs and multi-specifics—at a structured cost, diversifying pipeline risk beyond internally developed programs and Seagen assets. If several progress to Phase 3, Pfizer lengthens its late-decade growth runway without full upfront capital commitment.